Darolutamide in prostate cancer: Indication of considerable added benefit
Up to now, adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) at high risk of developing metastatic disease usually continued their conventional androgen deprivation therapy (ADT) while the cancer ...
Aug 3, 2020
0
4